ArticleThe oncologist2023
Correction to: An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer.
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.